|
Netherlands Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Netherlands Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for the Netherlands .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Dutch pharmaceutical and healthcare industry.
Competitive intelligence, Dutch pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Dutch market.
The Netherlands Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Netherlands Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Dutch pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on the Netherlands to test other views – a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Dutch Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in the Netherlands .
- Exploit The Latest Competitive Dutch Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in the Netherlands .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Netherlands Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Netherlands Pharmaceuticals And Healthcare Industry SWOT |
| Netherlands Political SWOT |
| Netherlands Economic SWOT |
| Pharmaceutical Business Environment Ratings |
| Table: Western European Pharmaceutical Business Environment Ratings |
| Limits to Potential Returns |
| Risks to Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Pricing and Reimbursement |
Chapter - Industry Developments |
| Healthcare Sector |
| Healthcare Insurance |
| Table: Key Points – Dutch Health Insurance Act, January 1 2006 |
| Epidemiology |
| Table: Disease Burden In Western Europe |
| Pharmaceuticals Sector |
| Recent Domestic Companies' Activities |
| Recent Foreign Companies' Activities |
| Wholesale and Retail Sector Developments |
| Research and Development Sector |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: The Netherlands Drug Market Forecast Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Netherlands Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Netherlands - Economic Activity |
| Prescription Market Forecast |
| Table: The Netherlands' Prescription Drug Market Forecast Indicators, 2004-2013 (US$mn unless otherwise stated) |
| OTC Market Forecast |
| Table: The Netherlands OTC Drugs Market Forecast Indicators, 2004-2013 (EURmn unless otherwise stated) |
| Generics Market Forecast |
| Table: The Netherlands' Generics And Branded Market Forecast Indicators, 2004-2013 |
| Export/Import Forecasts |
| Table: The Netherlands' Pharmaceutical Trade Forecast Indicators, 2004-2013 (US$bn) |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Multinational Manufacturers |
| Merck & Co |
| Pfizer |
| GlaxoSmithKline (GSK) |
| Sanofi-Aventis |
| Novartis |
| Indigenous Manufacturers |
| Akzo Nobel |
| DSM |
| Qiagen |
| Pharming Group |
| Crucell |
Chapter - Country Snapshot: Netherlands Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2000-2005 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Netherlands Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI calculates Netherlands pharmaceutical expenditure to have been EUR5.90bn (US$8.68bn) in 2008. By 2013, we expect the total amount spent on prescription and OTC medicines to have reached a value of EUR6.83bn equating to a compound annual growth rate (CAGR) of 3.0%. In US dollar terms, however, as a result of the weakening euro, drug market expenditure will fall to US$8.65bn in 2013.
In BMI’s Business Environment Rankings for 2009, the Netherlands is ranked 8th out of the 9 Western European markets surveyed. Globally, the Netherlands is ranked in 15th position just below Australia and Italy, after falling two places in Q209.
BMI calculates per capita drug expenditure to have been US$529 in 2008.The Dutch pharmaceutical market should show strong growth over the forecast period due to high prices of new drugs, more patients with chronic illnesses and an ageing population. The strong growth is partly also due to the fact that the Netherlands has one of the lowest per capita drug expenditure figures in the region.
Pharmaceutical and healthcare sales are generally resistant to economic downturns. However, the ongoing global financial crisis has forced governments and consumers to re-evaluate how much they spend on medicines. With the effects of the credit crisis still unfurling BMI, believes that the growth in Dutch drug sales may decline over the next 12-18 months. The depreciation of the euro against the US dollar will work in favour of the pharmaceutical export sector, although the falling demand in other sluggish eurozone economies will dampen its growth.
In January 2009 it was reported that the Dutch government bailed out health institutions of the Netherlands by funding them approximately EUR73mn over the last decade. The fund went to 34 establishments including the Vijverdal psychiatric centre in Maastricht, which received around EUR9.5mn. The fund provided by the government is expected to be utilised for improving the conditions of health institutions in the Netherlands. BMI calculates healthcare expenditure in the Netherlands to have reached a value of US$83.0bn in2008. By 2013 we expect this to have reached a value of US$85.7bn.
In company news, Netherlands-based biotechnology company Pharming Group announced that, during 2008, its unaudited net loss increased to EUR26mn as compared to EUR21.4mn in 2007. During the same period, net cash from operating activities increased marginally by 0.92% year-on-year (y-o-y) to EUR21.9mn and revenues remained broadly the same at a level of EUR0.7mn.
|
Netherlands Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |